LRMR
Larimar Therapeutics, Inc.
$2.16
-0.37
(-14.62%)
Mkt Cap
224.39M
Volume
2,563,328
52W Range
2.135-6.42
Sector
Healthcare
Beta
0.69
EPS (TTM)
-1.99 USD
P/E Ratio
-1.68
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (165.67M) | (80.60M) | (36.95M) | (35.35M) | (50.64M) | (42.33M) | (23.13M) | (61.37M) | (52.03M) | (57.88M) | (74.29M) | (36.57M) |
| EPS | -2.27 | -1.32 | -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 |
| Free Cash Flow | (113.29M) | (71.28M) | (33.62M) | (27.67M) | (42.44M) | (42.26M) | (22.78M) | (51.59M) | (43.84M) | (52.63M) | (60.15M) | (28.30M) |
| FCF / Share | -1.55 | -1.16 | -0.77 | -1.07 | -2.47 | -3.56 | -2.47 | -19.21 | -19.18 | -23.14 | -26.98 | -11.71 |
| Operating CF | (113.20M) | (70.76M) | (33.46M) | (27.57M) | (42.10M) | (42.20M) | (22.70M) | (51.49M) | (43.78M) | (51.98M) | (59.55M) | (28.24M) |
| Total Assets | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M | 104.69M | 5.20M | 121.76M | 105.51M | 131.62M | 189.11M | 117.52M |
| Total Debt | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M | 6.52M | 97,000 | 20.64M | 20.00M | 3.59M | 6.39M | 7.56M |
| Cash & Equiv | 85.41M | 33.22M | 26.75M | 26.82M | 70.10M | 68.15M | 1.01M | 49.33M | 40.78M | 32.35M | 35.59M | 58.10M |
| Book Value | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M | 89.69M | (694,000) | 93.27M | 78.22M | 121.73M | 169.11M | 104.44M |
| Return on Equity | -2.12 | -0.47 | -0.45 | -0.32 | -0.79 | -0.47 | N/A | -0.66 | -0.67 | -0.48 | -0.44 | -0.35 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (32.78M) | (29.61M) | (62.50M) | (47.71M) | (26.18M) | (29.28M) | (28.82M) | (15.50M) | (21.63M) | (14.65M) | (12.99M) | (9.06M) |
| EPS | -0.30 | -0.35 | -0.73 | -0.61 | -0.41 | -0.46 | -0.45 | -0.24 | -0.34 | -0.27 | -0.30 | -0.21 |
| Free Cash Flow | (44.16M) | (44.61M) | (38.53M) | (28.78M) | (19.40M) | (26.59M) | (21.99M) | (24.61M) | (14.26M) | (10.41M) | (9.51M) | (9.20M) |
| FCF / Share | -0.43 | -0.52 | -0.45 | -0.37 | -0.30 | -0.42 | -0.34 | -0.39 | -0.22 | -0.19 | -0.22 | -0.21 |
| Operating CF | (44.03M) | (44.61M) | (38.53M) | (28.75M) | (19.38M) | (26.54M) | (21.82M) | (24.55M) | (13.99M) | (10.41M) | (9.34M) | (9.20M) |
| Total Assets | 165.30M | 208.51M | 145.84M | 187.35M | 149.99M | 170.18M | 200.22M | 219.02M | 237.16M | 248.21M | 95.94M | 103.95M |
| Total Debt | 4.96M | 3.78M | 4.07M | 4.35M | 4.61M | 4.87M | 5.12M | 5.36M | 5.59M | 5.34M | 5.55M | 5.39M |
| Cash & Equiv | 92.69M | 177.91M | 85.41M | 90.14M | 20.59M | 21.13M | 33.22M | 35.07M | 32.31M | 110.12M | 26.75M | 38.72M |
| Book Value | 127.38M | 158.03M | 78.08M | 139.04M | 119.85M | 144.27M | 171.81M | 198.40M | 211.40M | 230.84M | 81.72M | 92.71M |
| Return on Equity | -0.26 | -0.19 | -0.80 | -0.34 | -0.22 | -0.20 | -0.17 | -0.08 | -0.10 | -0.06 | -0.16 | -0.10 |
LRMR News
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR